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Abstract
Over 130 million people are infected chronically with hepatitis C virus (HCV), which, together with HBV, is the leading cause
of liver disease. Novel small molecule inhibitors of Hepatitis C virus (HCV) are needed to complement or replace current
treatments based on pegylated interferon and ribavirin, which are only partially successful and plagued with side-effects.
Assembly of the virion is initiated by the oligomerization of core, the capsid protein, followed by the interaction with NS5A
and other HCV proteins. By screening for inhibitors of core dimerization, we previously discovered peptides and drug-like
compounds that disrupt interactions between core and other HCV proteins, NS3 and NS5A, and block HCV production. Here
we report that a biotinylated derivative of SL209, a prototype small molecule inhibitor of core dimerization (IC50 of 2.80 mM)
that inhibits HCV production with an EC50 of 3.20 mM, is capable of penetrating HCV-infected cells and tracking with core.
Interaction between the inhibitors, core and other viral proteins was demonstrated by SL209–mediated affinity-isolation of
HCV proteins from lysates of infected cells, or of the corresponding recombinant HCV proteins. SL209-like inhibitors of HCV
core may form the basis of novel treatments of Hepatitis C in combination with other target-specific HCV drugs such as
inhibitors of the NS3 protease, the NS5B polymerase, or the NS5A regulatory protein. More generally, our work supports the
hypothesis that inhibitors of viral capsid formation might constitute a new class of potent antiviral agents, as was recently
also shown for HIV capsid inhibitors.
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Introduction
Hepatitis C chronically infects over 130 million people
worldwide [1–2]. There is no vaccine available and standard-of-
care treatment is based on a combination of pegylated interferon
and ribavirin, which has a poor response rate and is plagued with
severe side-effects [3–4]. The search for targeted therapeutics for
HCV has reached a major milestone with the recent FDA
approval of two specific protease inhibitors [5–6], nearly ten years
after the initial discovery of the efficacy of such agents [7]. Initially,
these new drugs will still need to be administered in combination
with the standard-of-care combination of pegylated interferon and
ribavirin. The next advance will most likely be the replacement of
the non-selective interferon by a second targeted antiviral, directed
against another HCV protein, the RNA-dependent RNA
polymerase, NS5B [8–10] and if necessary, a third antiviral, eg.
the most recent discovered inhibitor of the regulatory protein
NS5A [11–12].
A number of obstacles remain. The new anti-NS3 protease
drugs are selective for genotype 1, where the greatest need exists in
the Western countries, since more than half of patients infected
with strains of this genotype are not cured by the interferon plus
ribavirin combination. Even though genotype 1 infections
constitute more than half of all cases, there are five other major
HCV genotypes for which novel pan-genotypic drugs are urgently
needed. Furthermore, the use of target-specific treatments
inevitably leads to emergence of resistant strains, and the first
mutants have already been reported [13–14]. Therefore it will be
necessary to continuously develop novel combination therapies
involving drugs directed against multiple targets.
Core, the capsid protein of HCV, could be a valuable target for
such future drug development [15]. Core is responsible for
assembly and packaging of the HCV RNA genome to form the
viral nucleocapsid [16]. Core dimers and higher-order oligomers
associate on lipid droplets and endoplasmic reticulum with other
HCV proteins thus acting as essential elements of viral particle
assembly possibly through dimerization-driven interaction with
NS3 [17] and other HCV proteins, including NS5A [18]. Core is
the least variable of all ten HCV proteins in clinical isolates of
infected patients, and is very well conserved among the six HCV
genotypes. Core plays a key role in the HCV life cycle during
assembly and release of the infectious particle [19]. Inhibitors of
capsid assembly may interfere with both uncoating of the viral
particle upon infection, formation of new particles and even
destabilization of assembled virions, as was recently demonstrated
for an inhibitor of HIV capsid dimerization ([20]; Kota and
Strosberg, unpublished results).
Inhibition of HCV core dimerization by peptides was reported
previously [21]. Transfer-of-energy assays revealed that the N-
terminal 106 residue fragment of core (core106) is sufficient to
achieve 91% inhibition, and that 15- to 18-residue peptides
derived from the homotypic region (positions 82–106) inhibited
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[21–22]. Physicochemical properties of binding of the peptides to
core were measured by Fluorescence Polarization Light analysis
(apparent Kd of 1.9 mM), and by Surface Plasmon Resonance
characterization of binding to mature core (apparent Kd of
7.2 mM [21]). Drug-like small molecules, identified using the
assays developed to characterize the core-derived peptide
inhibitors, displayed half-maximal inhibition of core dimerization
and HCV infectivity at 90 nM concentrations [23]. However,
evidence for direct binding to HCV core protein in cells has lacked
so far. We show here that a biotinylated derivative of SL209, one
of these small molecule inhibitors, directly binds to HCV core
presumably at the site of viral assembly in infected cells. Ligand-
based affinity isolation performed on lysates of HCV-infected cells
or on recombinant HCV proteins demonstrated that the presence
of core is required to retain other HCV proteins on the affinity-gel,
thus confirming the central role of core in virion assembly.
Materials and Methods
Compounds, Proteins, Antibodies, Cells, Replicon, and
Viruses
Compounds SL201, SL209 and SL231, and analogues were
made at the Center for Chemical Methodology and Library
Development (CMLD) at Boston University (BU), Boston, and
their synthesis was described previously as compound 15, and 17
in Wei et al., 2009 and as compound 1 and 2 in Ni et al., 2011
[23–24] respectively. SL209-biotin was prepared as indicated
below. HCV core106 (1–106 residues) [21] and core169 (1–169
residues) [21], NS3 helicase (167–631 residues) [17] and NS5A
(30–447 residues) [25], as well as their GST and Flag-tagged
versions of proteins were produced in E. coli and purified by Ni-
NTA affinity chromatography as described previously [17,21–
22,25]. NS5A protein was provided by Drs. I. Herrera-Angulo and
T. Tellinghuisen (TSRI-Florida). Antibodies were obtained from
commercial sources: anti-GST (Sigma–Aldrich), anti-core (MA1-
080) (Thermo Scientific), anti-NS3 [H23] (Ab138830-Abcam),
anti-LAMP1 (ab-24170-Abcam), horseradish peroxidase (HRP)-
conjugated secondary antibodies (Jackson ImmunoResearch) or as
a gift: anti-core polyclonal (R-308) from Dr. J. McLauchlan, anti-
NS5A [9E10] from Dr. T. Tellinghuisen. The hepatoma Huh-7.5
cells were kindly provided by Dr. F. Chisari, (TSRI, California).
The HCV 2a genotype pSGR-JFH1 subgenomic replicon, the
HCV 2a strain JC1 were kindly provided by Dr. T. Tellinghuisen,
Dr. C. Rice and Dr. T. Wakita.
Synthesis of Biotinylated SL209
Dimethyl8-(5-aminopentyl)-4-benzyl-3-oxo-1,2,3,4,7a,8-hexahydroindo-
lo[2,3-d][1,8]naphthyridine-6,7-dicarboxylate (2). The mixture of azide
1 (Ni et al, 2011 [23], 37.0 mg, 66 mmol), triphenylphosphine
(52.3 mg, 0.20 mmol) and water (12.0 mg, 0.66 mmol) in THF
(1 mL) was allowed to stir at 50uC for 5 hr in a sealed microwave
tube. The solution was then concentrated under high vacuum to
remove the solvent, and the residue was purified via flash
chromatography on silica gel, eluting with dichloromethane:-
methanol (5:1, Rf 0.1) to give crude amino compound as a yellow
oil (35.0 mg), which was used in the next step without further
purification.
Biotinylated SL209. A mixture of amine 2 (35.0 mg, 66 mmol) and
Biotin-X (30.0 mg, 66 mmol) in anhydrous THF/DMF (1:1,
1 mL) was allowed to stir at room temperature overnight (12 hour)
in a sealed microwave tube under argon. The solution was
concentrated under high vacuum and the residue was purified via
prep: HPLC (acetonitrile in H2O 10–40%) to give biotinylated
SL209 as a yellow oil (37.0 mg, 71% over 2 steps), SiO2 Rf=0.4
(dichloromethane:methanol=5:1). Purity (100%) confirmed by
LC-MS (Fig. 1).
AlphaScreen assay
The core106 Amplified Luminescent Proximity Homogenous
Assay screen (AlphaScreen) assay was developed as described in
Kota et al 2009 [21]. AlphaScreen utilizes photoactive donor and
acceptor beads which recognize specific tags on interacting
proteins [26]. The biological interaction between proteins brings
the beads in close proximity, and triggers a cascade of chemical
reactions. When the donor bead is laser-excited at 680 nm, it
converts the ambient oxygen into singlet oxygen which reacts with
the chemiluminescer in the acceptor bead which in-turn activates
fluorophores contained within the same acceptor bead to emit
light at 520–620 nm. Singlet oxygen has a very short half life and
cannot diffuse more than 200 nm. Hence this cascade of reactions
can only occur when the interacting proteins are in close
proximity. For the core106 AlphaScreen the recombinant purified
proteins were diluted to working concentrations in ‘protein buffer’
(100 mM HEPES pH 7.5, 1 mM EDTA, 5 mM DTT, 0.1%
CHAPS, 10% glycerol). The donor and acceptor beads were
diluted to working concentrations in ‘bead buffer’ (20 mM HEPES
pH7.5, 125 mM NaCl, 0.1% BSA, 0.1% CHAPS). GST-fused
core106 and Flag-fused core106 were used at a concentration of
150 nM each. The untagged core106 domain (10 mM) was added
to the proteins as a reference inhibitor, or SL209 (15 mM), or
SL209-biotin (15 mM) were evaluated on core–core interaction.
GST-core106, inhibitors and then Flag-core106 were incubated at
room temperature for 1 hour. Then anti-Flag acceptor beads
(Perkin Elmer Life Sciences), diluted to a final concentration of
20 mg/ml in bead buffer were added to the plate and incubated for
1 hour at room temperature. Finally, glutathione donor beads
(Perkin Elmer Life Sciences) were added to the proteins at a final
concentration of 20 mg/ml. The assays were executed in a white
384 well Packard opti plate (Perkin Elmer Lifesciences) and were
Figure 1. Scheme for synthesis of Biotinylated SL209.
doi:10.1371/journal.pone.0032207.g001
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control compared to the inhibition by either SL209 or SL209-
biotin were analyzed using unpaired student t-test. SL209 and
SL209-biotin were also dosed with a 4-fold dilution from 160 mM
to 150 pM. The IC50 values were calculated using GraphPad
Prism.
Co-precipitation
Huh-7.5 hepatoma cells were grown for 24 hours before
electroporation with infectious HCV. At day 4 post-electropora-
tion, the supernatant was removed and cells were lysed in 400 ml
of lysis buffer (PBS with 1% Triton X-100, 1 mM PMSF, and
protease inhibitor cocktail) and stored at 220uC. The presence of
HCV proteins core, NS3 and NS5A in cell lysate was verified by
immunoblotting using anti-core, anti-NS3 and anti-NS5A anti-
bodies. For Streptavidin pull-down, 50 mM of SL209-biotin was
immobilized on Streptavidin-agarose beads and was incubated
with 80 ml of cell lysate in incubation buffer (20 mM Tris, pH8.0,
150 mM NaCl, 10% glycerol, 0.05% Triton X-100) for 2 hours at
room temperature under end-over-end agitation. As control,
50 mM of free biotin was incubated with cell lysates. The beads
were washed 3 times and centrifuge at 5000 g for 1 minute using a
SigmaPrep
TM spin column and boiled in the SDS loading buffer
for 5 minutes, and the pulled-down proteins were detected by
immunoblotting, using specific antibodies. One-twentieth of the
lysates was included in the blots as input control. For the co-
precipitation of core106 or core169 by SL209-biotin, 50 mMo f
SL209-biotin was incubated with 10 mg of core106, core169 or
control protein CTD (C-Terminal Domain of HIV capsid protein
CA). To investigate whether SL209-biotin binds NS3 and NS5A
directly, 50 mM of SL209-biotin was immobilized on Streptavidin
agarose beads and was incubated with either 80 ml of PSGR
replicon lysates or 10 mg of either recombinant NS3 or NS5A. To
confirm the need for core in mediating the binding of SL209-
biotin to NS3 or NS5A, 10 mg of core106 was spiked into the
replicon lysates and co-precipitation was carried out as described
above for the replicon lysate. As a control, 10 mg of CTD was
spiked into the replicon lysate and co-precipitated with SL209-
biotin.
Immunoblotting analysis
HCV lysate proteins were separated electrophoretically on a 4–
20% Tris glycine gradient gel by SDS-PAGE, transferred onto a
nitrocellulose membrane which was saturated with 5% milk in
PBS at room temperature for 1 hour. After incubation with
alternate protein-specific primary antibodies overnight, the
membrane was washed three times with PBS containing 0.01%
tween-20 and three times with PBS. Species-specific HRP-tagged
secondary antibody was added to the membrane at room
temperature for 2 hours. After the incubation, the membrane
was washed three times with PBS containing 0.01% tween-20 and
three times with PBS. Then the membrane was developed using a
HRP-specific chemiluminescent substrate.
Cell Culture and virus production
HCV was produced using previously published protocols [27–
29] and [30–32]. The plasmid containing HCV RNA was
linearized using XbaI and the overhangs were removed by
addition of mung bean nuclease. The templates were purified
using a PCR cleanup kit (Qiagen, Valencia,CA) and 2 mg of this
reaction was used as a template for RNA transcription. The
transcription reaction was performed using a T7 RNA transcrip-
tion kit (Ambion, Ausitn,TX). After a 3 hour synthesis reaction at
37uC RNA was DNase-treated and purified using Rneasy
minicolumns (Qiagen, Valencia, CA). RNA concentrations were
analyzed by specotrophotometry and stored frozen at 280uC until
use. The Huh-7.5 hepatoma cells were routinely cultured in
Dulbecco’s modified Eagle medium supplemented with 10% heat
inactivated fetal bovine serum, 1X Pen-Strep-Gln and 1X non-
essential amino acid at 37uC with 5% CO2 and 95% relative
humidity in 15 cm dishes. For RNA transfection, cells were
washed with phosphate buffered saline (PBS), trypsinized, and
resuspended in complete growth medium. Cells were then
pelleted, washed with ice-cold PBS, and resuspended in ice-cold
PBS at 5610
6 cells/ml. 10 mg of RNA transcripts were mixed with
400 ml of cells and placed into a 2 mm gap electroporation cuvette
(BTX Genetronics, San Diego, CA) and electroporated with five
pulses of 99 mSec at 860 V over 1.1 seconds in an ECM830
electroporator (BTX Genetronics). After a 30 minute recovery
period, cells were mixed with complete growth medium and
plated. Subgenomic replicon pSGR-JFH1 cell line was grown
under 1 mg/mL G418 selection in the same conditions as the
Huh-7.5 cells.
Immunofluorescence Microscopy
Naı ¨ve Huh-7.5 cells were infected with HCV with or without
SL209-Biotin in LabTek II 4-well chamber slides for 3 days.
Infected cells were washed twice with PBS (phosphate-buffered
saline) and then fixed with fixative solution, permeabilized with
digitonin, and blocked following the protocol previously published
[33]. After washing with PBS, cells were incubated with anti-core
(MA1-080 or R308) or anti-NS5A (9E10) primary monoclonal
antibodies and then incubated with anti-mouse secondary
fluorescent antibodies Alexa555 and streptavidin-Alexa488 (In-
vitrogen, Carlsbad, CA) for 1 hour at room temperature. Cells
were finally washed with PBS and mounted with Prolong Gold
mounting medium with DAPI (Invitrogen, Carlsbad, CA). Images
were taken on an Olympus FV1000 confocal laser scanning
microscope (Olympus Corporation, Tokyo, Japan). For visualiza-
tion of the lipid droplets, cells were stained with BODIPY lipid
probes 556/568 (Invitrogen, Carlsbad, CA). The percent inhibi-
tion of HCV infection by SL209 in IHC data was determined by
microscopic observation.
Inhibition of HCV production in Huh-7.5 cells
HCV infectious supernatant was made by electroporation of
HCV RNA into naı ¨ve Huh-7.5 cells in 15 cm dishes, incubated for
72 hours, and then infectious culture supernatants were collected
and spun to remove cell debris. The viral titer was calculated by
limiting dilution assay (see below) and all inhibition assays were
performed at a Multiplicity Of Infection (MOI) of 5 to 8. For
inhibition assays, naı ¨ve Huh-7.5 cells were seeded into 24-well
plates and incubated for 24 hours to allow adhesion. The
compound was prepared in HCV-infected cell supernatant by
making 1:10 serial dilutions from 100 mM down to 0.001 mM, was
added to cells and incubated for 24 hours. The next day, cell
culture media was removed from each well and replaced with the
same dilutions of compound in fresh complete media, added to
cells, and incubated for another 48 hours (previously referred to as
T1) [17,23]. Supernatant from this time point was then transferred
to naı ¨ve cells for 24 hours before removing culture media and
replacing with fresh complete media, without adding new
compound for the remainder of 72 hours (previously referred to
as T2) [17,23]. Two stages of viral infection were studied: T1,
corresponding to the initial 72 hour culture of naı ¨ve cells infected
in the presence of the inhibitor, and T2, corresponding to the
second 72 hour passage through naı ¨ve cells [17].
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Cells were lysed and RNA was isolated using the RNeasy kit
(QIAGEN, Valencia, CA). DNA was generated using the Taqman
reverse transcription kit (Applied Biosystems, Foster City, CA).
Quantitative Real-Time polymerase chain reaction (PCR) was
performed in triplicate using LightCycler RNA Amplification Kit
HybProbe master mix (Roche) with Taqman MGB Probe 6FAM-
TATGAGTGTCGTGCAGCCTC-MGBNFQ on a model Light-
Cycler480 Real-Time PCR system (Roche). Data are expressed as
the mean fold change plus or minus standard error of 3 replicates
normalized to 100 mg total RNA. Primers used were forward
CTTCACGCAGAAAGCGTCTA and reverse CAAGCACCC-
TATCAGGCAGT.
Cytotoxicity Assay
To perform a XTT-based (2,3-bis(2-methoxy-4-nitro-5-sulfo-
phenyl)5-[(phenylamino) carbonyl]-2H-tetrazolium hydride) cyto-
toxicity assay [34], 8,000 cells in 100 mL volume of colorless
growth media were dispensed into each well of 96-well tissue
culture-treated microtiter plates and incubated overnight at 37uC
(5% CO2, 95% RH) to allow cells to adhere to the plate. The next
day, 100 mL of compound SL209 in DMSO (1.25% final DMSO
concentration) or DMSO alone were added to wells. Growth
medium with compound only was used to normalize the data to
account for background color. Next, the plates were incubated for
72 hours at 37uC (5% CO2, 95% RH). Solution of XTT-PMS
(phenazine methosulphate) was prepared in 1X PBS and added to
the cells in 50 mL volume to each well and incubated for 4 hours at
37uC (5% CO2, 95% RH). After equilibrating the plates to room
temperature for 10 minutes, optical density at 450 nm and
650 nm was measured on Biotek plate reader.
HCVcc Limiting dilution assay (Tissue Culture Inhibition
Dose-TCID50)
After wells were coated with poly-L-lysine (Sigma), naı ¨ve Huh-
7.5 cells were seeded at 8000 cells per well in 96-well plates and
incubated overnight at 37uC. Supernatants collected from HCV-
infected Huh-7.5 cells in presence or absence of compound were
titrated with serial 1:10 dilutions, from 0 to 10-6 dilution, in
complete media and added onto Huh-7.5 cells for 72 hours in the
HCVcc limiting dilution assay to determine TCID50 values. After
72 hours, cell supernatant was removed from each well and cells
were fixed with 100% cold methanol for 10–20 minutes at room
temperature. Immunohistochemistry was then performed on fixed
cells beginning with washing cells three times with PBS, then
followed by blocking for 1 hour at room temperature with
blocking buffer containing 0.5% (w/v) saponin, 1% (w/v) bovine
serum albumin (BSA), and 0.2% (w/v) dried non-fat milk in PBS.
Cells were incubated with 0.3% (v/v) hydrogen peroxide for
5 minutes at room temperature to block endogenous peroxidases
before washing cells three times with PBS. Cells were then
incubated with mouse 9E10 anti-NS5A antibody at a dilution of
1:20,000 in PBS buffer containing 0.5% (w/v) saponin for 1 hour
at room temperature or overnight at 4uC and washed three times
with PBS. Secondary goat anti-mouse conjugated with horse horse
radish peroxidase (HRP) antibody was prepared at 1:200 dilution
in PBS buffer containing 0.5% (w/v) saponin and incubated on
cells for 1 hour at room temperature. Cells were washed three
times in PBS. Bound peroxidase was developed with DAB
chromagen containing diaminobenzidine tetrahydrochloride (Vec-
tor Laboratories, Burlingame, CA). Wells with at least one positive
staining of NS5A were counted and the method of Reed and
Muench was used to calculate TCID50 values. Cell nuclei were
stained with hematoxylin 2 to record images (Richard Allan
Scientific, Kalamazoo, MI) under microscope [32].
Results
Biotinylation of small molecule SL209 does not affect
inhibition of dimerization
The AlphaScreen and TR-FRET assays developed for identi-
fying peptide disruptors of core106 or core169 dimerization were
used to identify small molecules with similar properties and lower
IC50, including SL201, its more potent analogue, SL209, and the
dimer of SL209, SL231.Their structures are presented in Figure 2A
[17,21–24]. To prove that small molecule inhibitors of core
dimerization directly bind to core, we prepared a biotinylated
derivative of SL209 (SL209-biotin) (Fig. 2A). We verified by the
core106 AlphaScreen assay that addition of the biotin tag did not
alter the inhibitory activity: SL209-biotin disrupts core dimeriza-
tion by 75% compared to 83% for untagged SL209, 74% for
SL231, and 66% for SL201, another analogue (Fig. 2B). To
eliminate the remote possibility that SL209-biotin binds to either
GST or Flag rather than to core106 itself, we developed two novel
AlphaScreen assays, one with GST-core106 and the other with
Flag-core106. Untagged SL209, when added at 10- to 15-fold
excess, inhibited the binding of SL209-biotin by respectively 83%
and 77% (Fig. 2C).
When analyzed by dose response studies, the IC50 value of
SL209-biotin for inhibition of core106 dimerization was calculated
to be 3.7 mM (Fig. 2D-right panel), compared to 2.8 mM for
SL209 (Fig. 2D-left panel).
SL209 and SL209-biotin reduce HCV RNA production and
HCV infectivity
The effects of SL209 and its biotinylated analogue on the Huh-
7.5 host cells of HCV were comparable: SL209-biotin was only
slightly more toxic to Huh-7.5 cells. Biotinylation did not affect the
capacity to reduce HCV RNA production, measured by Real
Time RT-PCR for SL209-biotin (EC50=4.80 mM; EC90=
47.3 mM) compared to SL209 (EC50=3.20 mM; EC90=33.9 mM)
(Fig. 2E and Table 1).
Streptavidin-agarose beads coated with SL209-biotin
bind HCV proteins
SL209-biotin bound to streptavidin-covered agarose beads
retains a 15 kDa band corresponding to recombinant core106
(Fig. 3A-top panel) and a 20 kDa band corresponding to core169
protein (Fig. 3A-middle panel), as shown by SDS-electrophoretic
analysis followed by immunoblotting with anti-core antibodies.
The biotin-only control did not retain either one of the proteins.
The control protein HIV CTD (C-terminal domain of HIV core
protein p24) was not retained by either biotin or SL209-biotin
confirming the specificity of the binding of SL209-biotin to core
(Fig. 3A-bottom panel). SL209-biotin retains native HCV NS3,
NS5A, and NS5B proteins contained within HCV-infected cell
lysates, in line with previously reported co-localization studies
(Fig. 3B). The NS5A protein detected here by Western blotting is
the hyper-phosphorylated form which runs at ,58 kDa. The
biotin-only coated streptavidin agarose beads did not retain any of
the proteins contained within the HCV-infected cell lysates. No
protein was captured on beads incubated with lysates of cells
expressing HCV pSGR subgenomic replicon, devoid of core
(Fig. 3C). SL209-biotin alone did not retain either NS3 helicase or
NS5A confirming the need for the presence of core to establish the
interaction (Fig. 3D). As further proof that core is required for
Binding of a Hepatitis C Virus Inhibitors
PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e32207Binding of a Hepatitis C Virus Inhibitors
PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e32207binding of SL209 to NS3 and NS5A, the pSGR replicon cell lysate
was spiked with recombinant core106, and analyzed by immuno-
blot: the capsid protein rescued the capture of NS3 and NS5A by
SL209-biotin (Fig. 3E). As a non-related protein control, HIV
CTD was spiked into the pSGR replicon lysate. Co-precipitation
analysis was carried out with SL209-biotin immobilized on
Streptavidin beads and incubated with replicon lysates spiked
with CTD and the resulting eluates were analyzed by immuno-
blotting. CTD did not rescue the capture of NS3 and NS5A by
SL209-biotin which confirmed that core is necessary for this
interaction (Fig. 3F).
Treatment with core dimerization inhibitors strongly
reduces the number of HCV infected cells, visualized by
anti-NS5A antibody
Huh-7.5 cells infected with HCV in presence of 0, 3, or 25 mM
of SL209, were washed after 24-hours, supernatant was replaced
with compound in fresh complete media and cells incubated for an
additional 48 hours. The cytotoxicity index CC50 value for SL209
measured on uninfected cells was found to be above 100 mM and
the EC50 value evaluated by Real Time RT-PCR on HCV-
infected cells was found to be 3.2 mM [23–24]. Immunohisto-
chemical staining of HCV NS5A in infected cells revealed that
SL209 used at 3.125 and 25 mM reduced the number of HCV-
infected cells substantially (Fig. 4). The results shown are
representative of 3 experiments with 4 wells per experiment.
The inhibition of HCV infection by SL209 in immunohistochem-
istry data was studied by microscopic observation. The EC50 value
by Tissue Culture Infectious Dose 50 limiting dilution assay was
calculated to be 5 mM.
Expression of core is required for intracellular staining by
SL209-biotin combined with streptavidin-fluorochrome
HCV-infected cells were treated with SL209-biotin and
Streptavidin-Alexa 488, and then stained by anti-core fluorescent
antibodies. The resulting characteristically dot-like images con-
firmed that the inhibitor was mostly found to be co-localized with
core often but not always on lipid droplets (Fig. 5A). No
streptavidin-mediated labeling was observed in untreated cells
(no SL209-biotin, therefore no Streptavidin-Alexa488 staining)
(Fig. 5B), in uninfected cells (Fig. 5C), or in cells expressing HCV
subgenomic replicon (no core therefore no SL209-biotin binding,
nor Streptavidin Alexa488 staining (Fig. 5D).
Discussion
Direct binding of inhibitors to core
We describe here the first evidence of binding, to the HCV
capsid protein, of a core dimerization inhibitor which reduces
HCV production and infectivity [23]. Direct binding was shown
by using a biotinylated derivative of small molecule drug-like
SL209, that largely maintained the HCV inhibitory properties of
the untagged compound. Using SL209-biotin absorbed on agarose
beads coated with streptavidin, direct physical interaction was
demonstrated by affinity-isolation performed on lysates of HCV-
infected cells, and confirmed with recombinant HCV proteins.
Affinity-binding was shown not only for core, but also for other
HCV proteins which were previously reported to be co-localized
with core on lipid droplets or on ER, namely NS3, NS5A, and
NS5B [18,33,35–36]. In the absence of core, neither NS5A nor
NS3 were retained on the SL209-biotin coated streptavidin beads.
Table 1. Anti-viral activity of SL209 and associated compounds.
Compound Core dimerization IC50 [mM] Cytotoxicity CC50 [mM]
HCV inhibition EC50 by
RT-PCR [mM]
HCV inhibition EC90 by
RT-PCR [mM]
SL201* 9.30 .320 8.80 92.80
SL209* 2.80 .100 3.20 33.90
SL231* 0.10 .100 2.50 25.90
SL209-biotin 3.70 .40 4.80 47.30
The compounds were analyzed in the core dimerization AlphaScreen assay to determine the IC50 values, on naı ¨ve Huh-7.5 cells to calculate the CC50 values and finally
on HCV infected (Multiplicity Of Infection – MOI – 5 to 8) Huh-7.5 cells to determine the EC50 values using Real Time RT-PCR.
‘‘*’’indicates previously published in Wei et al. [24], Strosberg et al. [15], Mousseau et al. [17], Ni et al. [23].
doi:10.1371/journal.pone.0032207.t001
Figure 2. Inhibition of core dimerization and of virus production by SL209-biotin and evidence for direct binding to core protein. In
an AlphaScreen assay, glutathione-coated donor beads and anti-flag antibody coated acceptor beads (20 mg/ml each) were used to monitor the
dimerization of GST- and Flag- tagged core106 proteins. GST-core106 (GC106) and Flag-core106 (FC106) were used at 150 nM each and core106 was
used at 1 mM as a reference inhibitor. A: Structures of SL201, SL209, SL231, and SL209-biotin. SL201, is a 513 Da small molecule inhibitor
originally identified to inhibit HCV core dimerization and virus production. SL209, is a SAR analogue of SL201. SL231, is a dimer of SL209. SL209-biotin
is a biotinlyated derivative of SL209. ‘‘*’’ indicates that structures of SL201, SL209, and SL231 have been previously published in Wei et al 2009 [24],
Strosberg et al 2010 [15], and Ni et al 2011 [23]. B: Levels of inhibition. Core106 inhibited 91% and small compounds inhibitors: SL201, SL209,
SL231 and SL209-biotin used at 15 mM inhibited respectively 66%, 74%, 83%, and 75% of core dimerization. C: Direct binding to GST-core106
(GC106) or Flag-core106 (FC106). In a novel AlphaScreen format GC106/SL209-biotin and FC106/SL209-biotin were mixed in 1:1000 ratio and
incubated. Streptavidin donor beads and glutathione coated acceptor beads at 20 mg/ml were used in the detection of the binding. Free SL209 at
50 mM inhibited 83% of SL209-biotin binding to GC106 and 77% of SL209-biotin binding to FC106. D: Dose response analyses. Inhibition levels
were analyzed in a dose response format. The compounds were dosed from 160 mM to 150 pM. The IC50 values for SL209 (right panel) and SL209-
biotin (left panel) were calculated as 3.7 mM and 2.8 mM using GraphPad Prism. E: Inhibition of HCV production. Inhibition of HCV production in
Huh-7.5 cells by SL209 and SL209-biotin was analyzed by adding serially diluted the compounds (individually) and virus onto naı ¨ve Huh-7.5 cells. The
supernatants of the cells after 3 days of culture were removed from the initial culture and added to naı ¨ve cells cultured for another 3 days. RNA was
purified from lysed cells and analyzed by Real-Time RT-PCR. EC50 values were calculated to be 3.2 mM and 4.8 mM for SL209 (right panel) and SL209-
biotin (left panel), respectively. EC90 values were calculated to be 33.9 mM and 47.3 mM for SL209 (right panel) and SL209-biotin (left panel),
respectively.
doi:10.1371/journal.pone.0032207.g002
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SL209-biotin binding is strong enough to retain core complexes
containing other HCV proteins. In support of this observation, co-
localization of core and NS5A proteins with SL209-biotin was
occasionally observed in HCV-infected cells using confocal
microscopy. Despite similar structures, SL209-biotin may thus
differ significantly from another inhibitor SL201, which had
earlier been shown to not only disrupt core dimerization, but also
inhibit interaction with NS3 helicase [17]. Alternatively, assay
conditions and their effect on avidity and affinity may play a major
role in dictating complex formation: in cells, or on agarose beads.
Protein-ligand complexes may be more stable than in the transfer-
of-energy assays optimized to measure inhibition of protein-
protein interactions [21–22].
Figure 3. Affinity isolation on SL209-biotin captures native and recombinant HCV core and core-associated proteins. SL209-biotin
was immobilized on streptavidin agarose beads and incubated with core106 (10 mg) or core169 (10 mg) proteins or lysates of Huh-7.5 cells infected
with HCV J6/JFH-1. The retained proteins were examined by immuno-blotting using anti-core, NS3, NS5A or NS5B antibodies. One-twentieth of the
cell lysate used in the assay was immuno-blotted for all proteins as the input control. As a control, the lysates were incubated with Biotin immobilized
on streptavidin agarose beads. As an additional control, a non-specific protein, CTD (C-terminal domain of HIV capsid protein, p24) was incubated
with immobilized SL209-biotin. A: SL209-biotin captures/co-precipitates recombinant core106 (top panel) and core169 proteins (middle panel) and
does not capture non-specific control protein CTD (bottom panel). B: SL209-biotin captures/co-precipitates core, NS3, NS5A, and NS5B from HCV-
infected Huh-7.5 cells, but C: not from replicon containing Huh-7.5 cell lysates. D: SL209-biotin does not co-precipitate recombinant NS3 and NS5A
proteins. E: Core protein added to replicon-containing Huh-7.5 cell lysates rescues co-precipitation of NS3 and NS5A. F: CTD protein added to
replicon-containing Huh-7.5 cell lysates does not rescue the co-precipitation of NS3 and NS5A.
doi:10.1371/journal.pone.0032207.g003
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Our earlier data suggested that the core-derived peptide
inhibitors bound to the core homotypic region, defined previously
as being located between positions 82 and 106 [21,37]. These
peptides share the sequence LYGNEGCGWAGWLLSPRG,
which was independently confirmed as an inhibitor of HCV
RNA production and infectivity [38]. Our small compound
inhibitors were identified using the same screening assays as the
ones developed to identify the peptides [23–24]. However, these
chemicals displayed IC50 values which were at least five times
lower than those of the peptide, suggesting that binding occurs
with higher affinity and possibly not on the same residues than the
peptide. EC50 values for HCV inhibition were about three times
and often much lower (nanomolar range) [23]. This could be
attributed to the fact that the inhibitors disrupt core dimerization,
a step which is necessary for core oligomers to form and remain
stable. As stated previously for the HIV-1 CA-1 inhibitor, a very
limited number of molecules may be sufficient to inhibit the
formation of a functional particle, an observation consistent with
the view that the whole viral capsid constitutes a single target with
multiple binding sites [39].
Intracellular labeling with biotinylated SL209 of
HCV-infected cells
Using SL209-biotin in combination with Streptavidin-Alexa
488, we showed by confocal immunofluorescence microscopy that
the presence of core is indispensable to observe any intracellular
staining: no labeling is observed in uninfected cells nor in cells
infected with HCV replicon or with HIV. Furthermore, SL209-
biotin staining coincides mostly, but not always, with immuno-
staining of core. Cellular co-staining of core and SL209-biotin
occurs often in sites where we could not detect lipid droplets,
mainly on Endoplasmic Reticulum (ER), as determined by staining
with LAMP1 (Lysosomal-associated membrane protein1), an ER
marker protein (Takahashi and Strosberg–unpublished data). This
observation is in line with the recent discovery that the core
protein of high-titer JC1 recombinant HCV virus, used in our
studies frequently exhibits an ER localization [40], rather than the
predominant lipid droplet localization of the core protein of JFH1
virus described in previous co-localization studies in HCV-infected
cells [33,41] and core-transfected uninfected cells [42]. Our choice
of using JC1 in preference to JFH1 was dictated by a much
improved level of viral production: whether this explains a possible
shift of virion production site and lower coating of lipid droplets is
not known [40].
The work presented here supports core, the HCV capsid protein
as a novel target for anti-HCV drug development. We show that an
inhibitor of capsid protein dimerization can specifically and directly
bind to core and core-based complexes with other HCV proteins.
This binding possibly results in disruption of assembly or in
disassembly of the viral particle, leading to reduction of infective
HCV particles. One added advantage of HCV core over the other
currently identified targets is its remarkable conservation among all
six genotypes, especially in the previously described ‘‘homotypic’’
region of dimerization [37]. Inhibitors optimized on the basis of
analogues described here have been found to be equally active on
core proteins of genotype 1a or 1b and to inhibit virus production of
a HCV 2a strain at nanomolar concentration. Despite several
attempts, no resistance mutant were so far found to emerge rapidly
in HCV 2a-infected cells grown in the presence of increasing
concentrations of core inhibitors.
Mechanism of action of SL209
While compound SL209 was identified as an inhibitor of core
protein dimerization, the mechanism by which it blocks HCV
production and infectivity is not yet known. Core multimerizes to
form the capsid of the virus, which together with the viral RNA,
forms the nucleo-capsid. Despite many attempts, core or even its N-
terminal mostly hydrophilic fragment core106, could not be
crystallized, so we do not yet have a good model for the assembled
capsid.While we can exclude any effect SL209 has on entry (no effect
on time-of-addition) [17] or replication (no effect on replicon
propagation [17]), it is likely that the inhibitor of core dimerization
acts on the viral capsid assembly or disassembly. By analogy with
HIV capsid inhibitors [20,39,43], several alternative mechanismscan
be considered for the molecular mode of action of SL209: inhibition
of uncoating of the particle upon penetration, blockade of correct
assembly of the capsid or destabilization of the assembled capsid.
Capsid proteins as targets for viral inhibitors
Several groups have recently proposed viral capsid protein as
targets for antiviral drug development for HBV and HIV. While
capsid-derived natural or stapled peptides displayed relatively modest
binding affinities, small compound inhibitors were described with
quite impressive affinities, IC50 values in solution, and EC50 values in
infected cells [39,43–46]. Cell-based screening yielded small molecule
compound PF-74, a potent inhibitor of HIV capsid assembly which
was shown to have both early stage and late stage effects, in contrast
to other compounds which only displayed late stage activity [20]. Co-
crystallization of compound PF-74 with the HIV CAprotein revealed
Figure 4. SL209 strongly reduces number of HCV-infected Huh-7.5 cells. Huh-7.5 cells seeded into 96-well plate were infected with HCV in
the presence of increasing amounts of SL209 and incubated for 72 hours. Cells were fixed with methanol and immunohistochemistry was performed
to stain cells for expression of the HCV NS5A protein with anti-NS5A (9E10) antibodies followed by rabbit anti-mouse HRP-conjugated secondary
antibody. We show here three representative fields containing large number of infected cells of which treatment with SL209 progressively reduces
numbers of cells stained with the anti-NS5A antibody. The left field (‘‘no compound’’) was treated with vehicle, and the following two fields were
treated with 3.125 mM and 25 mM SL209. Wells treated with 25 mM of SL209 showed a substantial reduction in HCV-infected cells. The cells were
counter stained with hematoxylin 2 to visualize the nuclei. Magnification is 106. The data are representative of 4 wells in each experiment and 3
different experiments.
doi:10.1371/journal.pone.0032207.g004
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peptides and in silico screened inhibitors [39,43,45–46]. The present
work demonstrates a direct localization of a biotinylated derivative of
a HCV inhibitor at the presumed site of viral particle assembly
strongly supports the validity of capsid inhibitors as useful molecular
probes to study capsid assembly and to serve as a basis for the
development of potential new antiviral drugs.
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Figure 5. Core is required for labeling by SL209-biotin. Huh-7.5 cells seeded into chamber slides were infected with HCV in the presence of
increasing amounts of SL209-biotin and incubated for 72 hours. Infected cells were probed for expression of core with anti-core antibody and
replicon cells were probed for both core and HCV NS5A protein respectively with anti-core (R-308) anti-NS5A (9E10) antibodies. Alexa555-coupled
secondary antibody was used to detect bound specific antibody. Huh-7.5 cells are stained with DAPI to localize nuclei, and studied by confocal
microscopy. In immunofluorescence studies of HCV-infected cells, treated with 2 mM of SL209-biotin (below the EC50 value of 4.8 mM) and
streptavidin-Alexa488 and labeled for core, SL209-biotin can be seen to penetrate the infected cells (Fig. 5A). No such labeling could be observed
when compound is not present (Fig. 5B), in uninfected cells (Fig. 5C), or in cells expressing HCV subgenomic replicon which produce NS5A but not
core (Fig. 5D). Magnification was 106with 36optical zoom and the images were cropped to display the field of interest.
doi:10.1371/journal.pone.0032207.g005
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